Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 625 of 2228 entries
View as:

CU Programme of Idarucizumab for Japanese Patients

Phase: N/A Priority: Normal
NCT ID: NCT02831660 Org: User:
Start: 07/22/16 End: 09/16/16 Due: 09/16/17

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02199899 Org: User:
Start: 03/31/99 End: - Due: -

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

Phase: N/A Priority: Normal
NCT ID: NCT05285982 Org: User:
Start: 04/06/22 End: 08/11/25 Due: 08/11/26

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT04540874 Org: User:
Start: 10/05/20 End: 11/12/20 Due: 11/12/21

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT05258110 Org: User:
Start: 03/18/22 End: 05/31/22 Due: 05/31/23

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02170740 Org: User:
Start: 11/30/99 End: - Due: -

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01169675 Org: User:
Start: 07/31/10 End: 11/30/12 Due: 11/30/13

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT06632457 Org: User:
Start: 12/02/24 End: 06/05/29 Due: 06/05/30

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase: N/A Priority: Normal
NCT ID: NCT06564441 Org: User:
Start: 10/03/24 End: 01/05/26 Due: 01/05/27

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Phase: N/A Priority: Normal
NCT ID: NCT04295005 Org: User:
Start: 11/16/20 End: 09/30/21 Due: 09/30/22

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Phase: N/A Priority: Normal
NCT ID: NCT06352437 Org: User:
Start: 06/10/24 End: 10/05/25 Due: 10/05/26

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase: N/A Priority: Normal
NCT ID: NCT04886804 Org: User:
Start: 07/02/21 End: 08/30/28 Due: 08/30/29

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Phase: N/A Priority: Normal
NCT ID: NCT00239538 Org: User:
Start: 01/31/03 End: 12/31/04 Due: 12/31/05

Observational Study of Meloxicam in Any Labeled Indication

Phase: N/A Priority: Normal
NCT ID: NCT02182739 Org: User:
Start: 01/31/01 End: - Due: -

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02182102 Org: User:
Start: 09/30/05 End: - Due: -

SITS-IVT in Patients >80 Years Study

Phase: N/A Priority: Normal
NCT ID: NCT04260347 Org: User:
Start: 05/14/20 End: 12/31/22 Due: 12/31/23

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02251210 Org: User:
Start: 05/31/01 End: - Due: -

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Phase: N/A Priority: Normal
NCT ID: NCT01696071 Org: User:
Start: 09/30/12 End: 06/30/13 Due: 06/30/14

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02242266 Org: User:
Start: 07/28/05 End: - Due: -

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Phase: N/A Priority: Normal
NCT ID: NCT02104947 Org: User:
Start: 05/06/14 End: 10/20/16 Due: 10/20/17

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01153698 Org: User:
Start: 08/31/10 End: 12/21/11 Due: 12/21/12

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Phase: N/A Priority: Normal
NCT ID: NCT01271725 Org: User:
Start: 05/24/11 End: 03/13/17 Due: 03/13/18

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01441596 Org: User:
Start: 10/31/11 End: 08/31/14 Due: 08/31/15

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00926289 Org: User:
Start: 06/30/09 End: - Due: -

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03648541 Org: User:
Start: 10/29/18 End: 05/03/23 Due: 05/03/24